Lactobacillus crispatus LV5 and Reduced Recurrent UTI

• Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.

  • 2011-05-15
  • RCT · n = 100
  • Clinical Infectious Diseases 52(10)
  • • A. Stapleton
    • Melissa Au-Yeung
    • T. Hooton
    • D. Fredricks
    • P. Roberts
    • C. Czaja
    • Yuliya Yarova-Yarovaya
    • T. Fiedler
    • Marsha E Cox
    • W. Stamm

  • PubMed: 21498386
  • DOI: 10.1093/cid/cir183

  2 Insights on

  • Reduced Recurrent UTI

  • High evidence
  • Highly Cited
  • Rigorous Journal

  Recurrent UTI occurred in 7/48 15% of women receiving Lactin-V compared with 13/48 27% of women receiving placebo (relative risk [RR], .5; 95% confidence interval, .2-1.2).

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  No